The share price of ECO Animal Health Group Plc surged on Monday after European regulators recommended marketing authorisation for its poultry vaccine ECOVAXXIN MS.
The AIM-listed company, which focuses on treatments for respiratory and enteric diseases in pigs and poultry, said the key milestone now establishes a roadmap for the commercial launch of the drug in the second half of 2026.
ECOVAXXIN MS is an immunisation against mycoplasma synoviae, which can cause air-sac and foot-pad lesions in poultry, which can result in a 5-10% reduction in the number of eggs laid by affected hens.
David Hallas, chief executive of ECO Animal Health, said he was "delighted" by the announcement from the the Committee for Medicinal Products for Veterinary Use of the European Medicines Agency.
"This marks an exciting time for the company, with further submissions expected over the next 12 months for additional products from our R&D pipeline, underpinning ECO's next phase of growth."
The stock was up 8.4% at 87.8p by 1136 GMT.